A study to learn how safe AZD6621 is, how well it works, and how it moves throughout the body over time, in adult male participants with Metastatic Prostate Cancer

Trial Identifier: D8020C00003
Sponsor: AstraZeneca
Start Date: September 2025
Primary Completion Date: March 2029
Study Completion Date: March 2029
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100142
CN Guangzhou, CN, 510060
CN Nanjing, CN, 2100008
JP Chuo-ku, JP, 104-0045
JP Hirakata-shi, JP, 573-1191
JP Kashiwa, JP, 277-8577
KR Seoul, KR, 03080
KR Seoul, KR, 5505
US, FL Tampa, FL, US, 33612
US, MI Grand Rapids, MI, US, 49546
US, NY Commack, NY, US, 11725
US, RI Providence, RI, US, 02903